Rahul Chattopadhyay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rahul Chattopadhyay has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Panagiota Anna Chousou
Department of Cardiology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust , Hill’s Road, Cambridge CB2 0QQ
2 shared publications - Peter John Pugh
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
2 shared publications Vassilios S Vassiliou
Department of Cardiac Medicine, Norwich Medical School, University of East Anglia , Norwich Research Park, Norwich, Norfolk NR4 7TJ
2 shared publications- Vassilios S. Vassiliou
Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK
2 shared publications - Elaine Soon
Department of Medicine University of Cambridge Cambridge UK
1 shared publication Gareth D Matthews
Department of Cardiology, Faculty of Medicine and Health Sciences, University of East Anglia , Norwich Research Park, Norwich, NR4 7TJ
1 shared publication
Latest Publications
A spike in disguise
She was commenced on cardiac monitoring for the detection of atrial fibrillation. While on the monitor, she was noted to be bradycardic with heart rates of 40 beats per minute. A 12-lead …
A spike in disguise
She was commenced on cardiac monitoring for the detection of atrial fibrillation. While on the monitor, she was noted to be bradycardic with heart rates of 40 beats per minute. A 12-lead …
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
The predictive value of left atrioventricular coupling index for ILR-detected atrial fibrillation following an embolic stroke of undetermined source in patients with sinus rhythm
The prediction of atrial fibrillation in high-risk populations is an important research area of modern atrial fibrillation care. One such population is the embolic stroke of undetermined source population, where appropriate anticoagulation might help reduce the annual stroke recurrence risk by 5%. In this study, individuals were categorized according to their tertile of left atrioventricular coupling index, a composite echocardiographic parameter that reflects both left atrial and ventricular size. Its association with the detection of an implantable loop recorder and subclinical atrial fibrillation was investigated. A retrospective single-centre cohort study was performed. A total of 296 embolic stroke of undetermined source patients, referred for an implantable loop recorder, who also underwent echocardiography, were screened. Of these, 230 cases had echocardiograms of sufficient quality to measure the left atrioventricular coupling index. Patients were categorized according to their left atrioventricular coupling index tertile, with tertile 1 being less than 16.97, tertile 2 being 16.97–23.9, and tertile 3 being greater than 23.9. Patients in the third left atrioventricular coupling tertile were more likely to develop atrial fibrillation of any duration, with a 1.9-fold increased univariable hazard ratio, although this association was not significant in longer duration of atrial fibrillation episode. This effect was no longer significant with stepwise multivariable analysis, suggesting that age was primarily mediating the effect seen in this study. Left atrioventricular coupling index was not an independent predictor of future implantable loop recorder-detected atrial fibrillation after adjustment for age in this cohort.
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
Open AccessThe predictive value of left atrioventricular coupling index for ILR-detected atrial fibrillation following an embolic stroke of undetermined source in patients with sinus rhythm
The prediction of atrial fibrillation in high-risk populations is an important research area of modern atrial fibrillation care. One such population is the embolic stroke of undetermined source population, where appropriate anticoagulation might help reduce the annual stroke recurrence risk by 5%. In this study, individuals were categorized according to their tertile of left atrioventricular coupling index, a composite echocardiographic parameter that reflects both left atrial and ventricular size. Its association with the detection of an implantable loop recorder and subclinical atrial fibrillation was investigated. A retrospective single-centre cohort study was performed. A total of 296 embolic stroke of undetermined source patients, referred for an implantable loop recorder, who also underwent echocardiography, were screened. Of these, 230 cases had echocardiograms of sufficient quality to measure the left atrioventricular coupling index. Patients were categorized according to their left atrioventricular coupling index tertile, with tertile 1 being less than 16.97, tertile 2 being 16.97–23.9, and tertile 3 being greater than 23.9. Patients in the third left atrioventricular coupling tertile were more likely to develop atrial fibrillation of any duration, with a 1.9-fold increased univariable hazard ratio, although this association was not significant in longer duration of atrial fibrillation episode. This effect was no longer significant with stepwise multivariable analysis, suggesting that age was primarily mediating the effect seen in this study. Left atrioventricular coupling index was not an independent predictor of future implantable loop recorder-detected atrial fibrillation after adjustment for age in this cohort.
- Open Access
- 27 June 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (6) , omae137
Educational case: a 46-year-old woman with palpitations and shortness of breath
In this educational case report, the journey of a woman with atrial fibrillation is discussed, to highlight contemporary management issues in atrial fibrillation. Issues discussed include decisions on anticoagulation, rate and rhythm control, the management of refractory high rates, and the genetic basis of atrial fibrillation.
- 27 June 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (6) , omae137
Open AccessEducational case: a 46-year-old woman with palpitations and shortness of breath
In this educational case report, the journey of a woman with atrial fibrillation is discussed, to highlight contemporary management issues in atrial fibrillation. Issues discussed include decisions on anticoagulation, rate and rhythm control, the management of refractory high rates, and the genetic basis of atrial fibrillation.
- Open Access
- 1 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0278527
The predictive value of abnormal P-wave axis for the detection of incident atrial fibrillation: A systematic review with meta-analysis
Introduction: There is growing interest in the prediction of incident atrial fibrillation (AF). The 12-lead electrocardiogram (ECG) has been a particularly rich target for possible prediction strategies.Purpose: The P-wave axis is an ECG parameter that reflects the dominant vector of atrial depolarisation and is usually 0° -75°. There is a large body of literature suggesting that AF reflects structural and conduction abnormalities of the atria, and thus the P-wave axis may represent a sensitive parameter to detect such changes.Methods: A systematic review and meta-analysis of published literature associating abnormal P-wave axis and the development of incident AF was performed. Electronic databases were systematically searched from inception to October 2021. A random-effects model with generic inverse variance weights was utilised to pool the most adjusted effect measure from each paper. A funnel plot was used to assess publication bias.Results: After excluding duplicate studies, 568 studies were screened. A total of eleven studies were identified that associated an abnormal P-wave axis with the subsequent detection of AF. The eight studies that considered abnormal P-wave axis as being 75° were pooled for meta-analysis. In the pooled studies a total of 78,222 patients were included with 5656 cases of incident atrial fibrillation identified. The meta-analysis of the studies suggested that an abnormal P-wave axis was associated with a pooled risk ratio of 2.12 (95% CI 1.49 to 3.01) for the detection of incident atrial fibrillation.Conclusion: This comprehensive systematic review and meta-analysis, indicates the positive association of abnormal P wave axis and future detection of AF. Utilisation of abnormal P-wave axis, alongside other parameters, may allow clinicians to better risk-stratify individuals at increased risk of AF, and thus identify those who may benefit most from prolonged cardiac monitoring or targeted anticoagulation.
- 1 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0278527
Open AccessThe predictive value of abnormal P-wave axis for the detection of incident atrial fibrillation: A systematic review with meta-analysis
Introduction: There is growing interest in the prediction of incident atrial fibrillation (AF). The 12-lead electrocardiogram (ECG) has been a particularly rich target for possible prediction strategies.Purpose: The P-wave axis is an ECG parameter that reflects the dominant vector of atrial depolarisation and is usually 0° -75°. There is a large body of literature suggesting that AF reflects structural and conduction abnormalities of the atria, and thus the P-wave axis may represent a sensitive parameter to detect such changes.Methods: A systematic review and meta-analysis of published literature associating abnormal P-wave axis and the development of incident AF was performed. Electronic databases were systematically searched from inception to October 2021. A random-effects model with generic inverse variance weights was utilised to pool the most adjusted effect measure from each paper. A funnel plot was used to assess publication bias.Results: After excluding duplicate studies, 568 studies were screened. A total of eleven studies were identified that associated an abnormal P-wave axis with the subsequent detection of AF. The eight studies that considered abnormal P-wave axis as being 75° were pooled for meta-analysis. In the pooled studies a total of 78,222 patients were included with 5656 cases of incident atrial fibrillation identified. The meta-analysis of the studies suggested that an abnormal P-wave axis was associated with a pooled risk ratio of 2.12 (95% CI 1.49 to 3.01) for the detection of incident atrial fibrillation.Conclusion: This comprehensive systematic review and meta-analysis, indicates the positive association of abnormal P wave axis and future detection of AF. Utilisation of abnormal P-wave axis, alongside other parameters, may allow clinicians to better risk-stratify individuals at increased risk of AF, and thus identify those who may benefit most from prolonged cardiac monitoring or targeted anticoagulation.
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Impact of the Covid-19 pandemic on the device therapy for patients with the heart failure
Introduction: Hospital admissions of patients with cardiovascular disease were markedly reduced in the UK in 2020 during the Covid-19 pandemic. In many institutions, including ours, patient care was redistributed from a specialty-based approach to a ward-based system, meaning some patients being admitted and managed under the care of non-specialist teams. Purpose: We wished to examine the impact of these changes on heart failure (HF) patients presenting during the pandemic and on appropriate delivery of complex device therapies. Methods: The study was undertaken in a large UK teaching hospital. The institution audit programme includes cardiac device therapy provision, aiming to ensure that implantable cardioverter defibrillators and cardiac resynchronisation therapy are offered to the target population in accordance with NICE guidance [Technology Appraisal 314]. In accordance with the guidance, patients admitted to hospital with serious ventricular arrhythmia, familial cardiac condition with high risk of sudden cardiac death (SCD), surgical repair of congenital heart disease (CHD) and patients with HF and LVEF<36% were identified from hospital coding. Findings during the pandemic (March to August 2020) were compared with the same period in 2019. Fisher's exact test was used to compare proportions. Results: Among non-HF patients, device therapy prescription was consistent in the two periods observed. Table 1 shows how many patients were eligible for device therapy and how many were offered it. Table 2 contains details of HF admissions, showing an 8% reduction in admissions during the pandemic. The proportion of patients eligible for device therapy did not change significantly. However, there was a significant reduction in the proportion of eligible patients who were offered device therapy (79% vs 94% p=0.03). In addition, during the pandemic there was a trend towards a greater chance of patients being considered too frail for device therapy (p=0.08). Among 12 patients overlooked for device therapy, 10 were not under the care of Cardiology. Among 31 patients considered too frail for device therapy, 26 were not under the care of Cardiology. Conclusion: During the Covid-19 pandemic, a modest reduction in HF hospital admission was observed with a marked fall in identification of patients eligible for device therapy. Possible explanations include intense pressure to discharge patients quickly, an increased perception of patient frailty during a crisis and the lack of recognition of indications for device therapy when patients are under the care of non-specialists. These findings suggest that cardiac services should actively look for HF patients who may have missed out on life-saving device therapies during the pandemic. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Open AccessImpact of the Covid-19 pandemic on the device therapy for patients with the heart failure
Introduction: Hospital admissions of patients with cardiovascular disease were markedly reduced in the UK in 2020 during the Covid-19 pandemic. In many institutions, including ours, patient care was redistributed from a specialty-based approach to a ward-based system, meaning some patients being admitted and managed under the care of non-specialist teams. Purpose: We wished to examine the impact of these changes on heart failure (HF) patients presenting during the pandemic and on appropriate delivery of complex device therapies. Methods: The study was undertaken in a large UK teaching hospital. The institution audit programme includes cardiac device therapy provision, aiming to ensure that implantable cardioverter defibrillators and cardiac resynchronisation therapy are offered to the target population in accordance with NICE guidance [Technology Appraisal 314]. In accordance with the guidance, patients admitted to hospital with serious ventricular arrhythmia, familial cardiac condition with high risk of sudden cardiac death (SCD), surgical repair of congenital heart disease (CHD) and patients with HF and LVEF<36% were identified from hospital coding. Findings during the pandemic (March to August 2020) were compared with the same period in 2019. Fisher's exact test was used to compare proportions. Results: Among non-HF patients, device therapy prescription was consistent in the two periods observed. Table 1 shows how many patients were eligible for device therapy and how many were offered it. Table 2 contains details of HF admissions, showing an 8% reduction in admissions during the pandemic. The proportion of patients eligible for device therapy did not change significantly. However, there was a significant reduction in the proportion of eligible patients who were offered device therapy (79% vs 94% p=0.03). In addition, during the pandemic there was a trend towards a greater chance of patients being considered too frail for device therapy (p=0.08). Among 12 patients overlooked for device therapy, 10 were not under the care of Cardiology. Among 31 patients considered too frail for device therapy, 26 were not under the care of Cardiology. Conclusion: During the Covid-19 pandemic, a modest reduction in HF hospital admission was observed with a marked fall in identification of patients eligible for device therapy. Possible explanations include intense pressure to discharge patients quickly, an increased perception of patient frailty during a crisis and the lack of recognition of indications for device therapy when patients are under the care of non-specialists. These findings suggest that cardiac services should actively look for HF patients who may have missed out on life-saving device therapies during the pandemic. Funding Acknowledgement: Type of funding sources: None.
- Open Access
- 19 August 2021
- Published by Wiley in Cardiology Research and Practice
- Vol. 2021, 1-11
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of their baseline diabetes status. Methods and Results. PubMed, Web of Science, and Cochrane library databases were systematically searched from inception until November 20th 2020. Eight studies consisting of 13,275 patients were included in the meta-analysis. For the total population, SGLT2 inhibitors reduced the risk of all-cause mortality (HR: 0.83; 95 CI: 0.750.91; I2 0), hospitalisation for HF (HR: 0.68; 95 CI: 0.610.75; I2: 0), CV death (HR: 0.82; 95 CI: 0.740.92; I2: 0), and hospitalisation for HF or CV death (HR: 0.72; 95 CI: 0.660.78; I2: 0). Subgroup analyses of the total population according to the diabetes status showed that SGLT2 inhibitors significantly reduced the risk of hospitalisation for HF (HR: 0.68; 95 CI: 0.61, 0.75; I2: 0), as well as the risk of hospitalisation for HF or CV death (HR: 0.72; 95 CI: 0.66, 078; I2: 0) and CV death (HR: 0.82; 95 CI: 0.74, 0.91; I2: 0). Conclusions. The results of this meta-analysis confirm the growing evidence in the literature of the favourable profile of SGLT2 inhibitors in cardiovascular outcomes and mortality in patients with heart failure regardless of the baseline diabetes status. This systematic review has been registered with PROSPERO (CRD42021224777).
- 19 August 2021
- Published by Wiley in Cardiology Research and Practice
- Vol. 2021, 1-11
Open AccessThe Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of their baseline diabetes status. Methods and Results. PubMed, Web of Science, and Cochrane library databases were systematically searched from inception until November 20th 2020. Eight studies consisting of 13,275 patients were included in the meta-analysis. For the total population, SGLT2 inhibitors reduced the risk of all-cause mortality (HR: 0.83; 95 CI: 0.750.91; I2 0), hospitalisation for HF (HR: 0.68; 95 CI: 0.610.75; I2: 0), CV death (HR: 0.82; 95 CI: 0.740.92; I2: 0), and hospitalisation for HF or CV death (HR: 0.72; 95 CI: 0.660.78; I2: 0). Subgroup analyses of the total population according to the diabetes status showed that SGLT2 inhibitors significantly reduced the risk of hospitalisation for HF (HR: 0.68; 95 CI: 0.61, 0.75; I2: 0), as well as the risk of hospitalisation for HF or CV death (HR: 0.72; 95 CI: 0.66, 078; I2: 0) and CV death (HR: 0.82; 95 CI: 0.74, 0.91; I2: 0). Conclusions. The results of this meta-analysis confirm the growing evidence in the literature of the favourable profile of SGLT2 inhibitors in cardiovascular outcomes and mortality in patients with heart failure regardless of the baseline diabetes status. This systematic review has been registered with PROSPERO (CRD42021224777).
- Open Access
- 9 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (3) , ytab063
Transfemoral cardiac resynchronization in a multi-comorbid patient
An 89-year-old female with severely impaired left ventricular function (ejection fraction biplane 27%) due to coronary artery disease, diabetes, and end-stage renal failure on haemodialysis, experienced repeated hospitalization due to heart failure decompensation. Electrocardiogram ( Supplementary Figure 1 ) demonstrated sinus rhythm with broad left bundle branch block (QRS duration 158 ms). Biventricular pacing was considered, but conventional approach via upper limb veins was unsuitable as she was on haemodialysis via a combination of left-sided fistula and right-sided tunnelled line. She was initially managed conservatively, as it was felt her comorbidities and vascular access concerns meant exposing her to the risks of complex device insertion was not in the patient’s best interest.
- 9 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (3) , ytab063
Open AccessTransfemoral cardiac resynchronization in a multi-comorbid patient
An 89-year-old female with severely impaired left ventricular function (ejection fraction biplane 27%) due to coronary artery disease, diabetes, and end-stage renal failure on haemodialysis, experienced repeated hospitalization due to heart failure decompensation. Electrocardiogram ( Supplementary Figure 1 ) demonstrated sinus rhythm with broad left bundle branch block (QRS duration 158 ms). Biventricular pacing was considered, but conventional approach via upper limb veins was unsuitable as she was on haemodialysis via a combination of left-sided fistula and right-sided tunnelled line. She was initially managed conservatively, as it was felt her comorbidities and vascular access concerns meant exposing her to the risks of complex device insertion was not in the patient’s best interest.